Australian Broker Call *Extra* Edition – Dec 02, 2024

This story features CAPSTONE COPPER CORP., and other companies. For more info SHARE ANALYSIS: CSC

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

CSC   EGL   FPH   HVN   MGH   NXL   PME (2)   PPE   QBE   WEB   WJL  

CSC    CAPSTONE COPPER CORP.

Copper – Overnight Price: $10.51

Moelis rates ((CSC)) as Buy (1) –

Moelis highlights Capstone Copper’s recent site tours of Chilean projects including Mantoverde, Mantos Blancos and Santo Domingo, showcasing strong operational progress and organic growth potential.

The Mantoverde sulphide project is now complete, notes the analyst, with commercial production declared and commissioning milestones achieved, supporting robust 2025 guidance of 111kt copper production at $1.83/lb costs (AISC).

The broker notes the Mantos Blancos upgrades, which have resolved prior operational issues, enabling sustainable processing rates. Exploration efforts at Mantoverde and adjacent areas are set to expand reserves, securing long-term production stability.

Moelis raises the target price to $14.50 from $14.00 and retains a Buy rating, citing a positive cash flow trajectory and potential value from the Santo Domingo project.

This report was published on November 29, 2024.

Target price is $14.50 Current Price is $10.51 Difference: $3.99
If CSC meets the Moelis target it will return approximately 38% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.

Forecast for FY24:

Moelis forecasts a full year FY24 dividend of 0.00 cents and EPS of 26.55 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 39.59.

Forecast for FY25:

Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 88.39 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.89.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EGL    ENVIRONMENTAL GROUP LIMITED

Industrial Sector Contractors & Engineers – Overnight Price: $0.27

Moelis rates ((EGL)) as Initiation of coverage with Buy (1) –

Moelis initiates coverage with a Buy rating and 35c target for environmental solutions and industrial services provider, Environmental Group. A “solid” earnings growth profile is supported by strong industry tailwinds and mandated demand in regulated industries,

Recurring revenue now accounts for over 50% of total group revenue, providing more visible earnings certainty, highlight the analysts. Solid growth is set to continue in core operating segments, while commercialising water treatment technology provides potential upside.

An “exciting” option, according to Moelis, is  the company’s highly effective, safe, and cheap option to treat per- and polyfluoroalkyl substances (PFAS) contaminated water.

This report was published on November 28, 2024.

Target price is $0.35 Current Price is $0.27 Difference: $0.078
If EGL meets the Moelis target it will return approximately 29% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.13.

Forecast for FY26:

Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.32.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

FPH    FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Medical Equipment & Devices – Overnight Price: $34.52

Wilsons rates ((FPH)) as Downgrade to Market Weight from Overweight (3) –

Wilsons notes Fisher & Paykel Healthcare’s first-half results included 19% revenue growth year-on-year, with solid performance in Hospital and Homecare segments.

Gross margin reached 61.9%, exceeding guidance, though the broker anticipates softer improvement ahead with potential headwinds in FY26.

NewApps consumables grew 27%, driven by adoption in new settings such as anaesthesia, while Homecare benefited from mask launches and durable resupply demand, explains the analyst.

Wilsons lowers profit  forecasts by between -2% to -4% for FY25-FY27, reflecting expectations for slower gross margin development. The rating is downgraded to Market Weight from Overweight, and the target eases to $34.93 from $35.

This report was published on November 29, 2024.

Target price is $34.93 Current Price is $34.52 Difference: $0.41
If FPH meets the Wilsons target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $23.06, suggesting downside of -33.2%(ex-dividends)
The company’s fiscal year ends in March.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 39.04 cents and EPS of 53.19 cents.
At the last closing share price the estimated dividend yield is 1.13%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 64.90.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 53.9, implying annual growth of N/A.
Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 64.0.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 44.09 cents and EPS of 63.84 cents.
At the last closing share price the estimated dividend yield is 1.28%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 54.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 66.8, implying annual growth of 23.9%.
Current consensus DPS estimate is 48.4, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 51.7.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

HVN    HARVEY NORMAN HOLDINGS LIMITED

Consumer Electronics – Overnight Price: $4.76

Jarden rates ((HVN)) as Overweight (2) –

Jarden highlights a positive trading update for Harvey Norman, observing sales momentum meeting or exceeding expectations across most markets. Australia remains steady, Europe is improving, while Asia is weaker.

The broker notes favourable consumer spending trends and sales recovery, driven by the replacement cycle and growing adoption of AI-embedded products.

Management reports stronger sales heading into November and December, further supported by easing interest rates in New Zealand.

Jarden retains an Overweight rating for Harvey Norman and maintains the target price of $4.90.

This report was published on November 28, 2024.

Target price is $4.90 Current Price is $4.76 Difference: $0.14
If HVN meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $4.95, suggesting upside of 4.0%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 27.00 cents and EPS of 34.70 cents.
At the last closing share price the estimated dividend yield is 5.67%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.72.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 32.1, implying annual growth of 13.5%.
Current consensus DPS estimate is 24.4, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 14.8.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 32.00 cents and EPS of 41.20 cents.
At the last closing share price the estimated dividend yield is 6.72%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.55.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 35.2, implying annual growth of 9.7%.
Current consensus DPS estimate is 26.5, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 13.5.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

MGH    MAAS GROUP HOLDINGS LIMITED

Building Products & Services – Overnight Price: $4.95

Wilsons rates ((MGH)) as Overweight (1) –

Maas Group’s 1H trading update reconfirmed FY25 underlying earnings (EBITDA) guidance of $215-245m, with a 40/60 1H:2H split due to renewable energy project delays and land sale timing., explains Wilsons.

Management announced three acquisitions in construction materials for -$252m, contributing FY25 pro forma revenue of $174-199m and earnings (EBITDA) of $34-38m.

Synergies from internalising volumes and cost efficiencies are expected to drive medium-to-long-term upside, in the broker’s view.

Wilsons raises FY25 earnings (EBITDA) by 6% and FY26 by 16%, with EPS accretion of 5% from FY26 onwards. The target is increased to $6.01 from $5.66. Overweight rating.

This report was published on November 29, 2024.

Target price is $6.01 Current Price is $4.95 Difference: $1.06
If MGH meets the Wilsons target it will return approximately 21% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 9.00 cents and EPS of 28.10 cents.
At the last closing share price the estimated dividend yield is 1.82%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.62.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 12.50 cents and EPS of 39.20 cents.
At the last closing share price the estimated dividend yield is 2.53%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.63.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

NXL    NUIX LIMITED

Software & Services – Overnight Price: $6.70

Moelis rates ((NXL)) as Initiation of coverage with Buy (1) –

Jarden initiates coverage on Nuix, a leader in investigative analytics and intelligence software, addressing the need to process large volumes of data.

As per the broker, management’s strategy focuses on adding automation tools powered by AI and unifying solutions tailored to specific use cases, including Data Privacy, Investigations, and Legal.

The recent launch of Neo, which integrates Nuix’s data collection engine with analysis and review capabilities, has driven higher Net Dollar Retention (NDR), notes the broker.

Jarden observes customers tend to increase spending over time and maintain long-term relationships with the company. The broker begins with a Buy rating and a $6.94 target.

This report was published on November 29, 2024.

Target price is $6.94 Current Price is $6.70 Difference: $0.24
If NXL meets the Moelis target it will return approximately 4% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 111.67.

Forecast for FY26:

Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 83.75.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PME    PRO MEDICUS LIMITED

Medical Equipment & Devices – Overnight Price: $251.89

Goldman Sachs rates ((PME)) as Buy (1) –

Highlighting the ongoing shift to cloud Picture Archiving and Communication Systems (PACS) across the industry, Goldman Sachs notes Pro Medicus has won a full-stack 10-year contract with Trinity Health in the US, valued at $330m, its largest contract to date.

Trinity operates in 26 states with 93 hospitals and over 9k physicians, including circa 650 radiologists. The contract is the first new customer win, excluding renewals and upgrades, in FY25, bringing forth a minimum $33m annualised value.

The broker believes the company’s Visage 7 software is an industry-leading solution, with speed and cloud capabilities separating it from the competition. Pro Medicus is also moving into adjacent solutions in cardiology and AI, offering potential significant upside.

Buy rated. Target price $221.

This report was published on November 29, 2024.

Target price is $221.00 Current Price is $251.89 Difference: minus $30.89 (current price is over target).
If PME meets the Goldman Sachs target it will return approximately minus 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $155.30, suggesting downside of -38.3%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Goldman Sachs forecasts a full year FY25 dividend of 54.00 cents and EPS of 107.00 cents.
At the last closing share price the estimated dividend yield is 0.21%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 235.41.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 104.3, implying annual growth of 31.6%.
Current consensus DPS estimate is 52.0, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 241.5.

Forecast for FY26:

Goldman Sachs forecasts a full year FY26 dividend of 69.00 cents and EPS of 136.00 cents.
At the last closing share price the estimated dividend yield is 0.27%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 185.21.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 143.2, implying annual growth of 37.3%.
Current consensus DPS estimate is 71.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 175.9.

Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

---

Wilsons rates ((PME)) as Overweight (1) –

Pro Medicus has secured its largest contract to date, a $330m, 10-year deal with Trinity Health, which fully integrates the Visage 7 platform in the cloud, observes Wilsons.

Trinity Health, a top-10 US IDN, provides significant scale and positions Pro Medicus as a leader in the radiology market, suggests the broker.

The analyst believes Trinity will serve as a luminary reference site, showcasing Pro Medicus’ ability to displace legacy PACS systems.

The new contract, alongside the recent $24m extension with NYU Langone Health, has driven upgrades to the broker’s FY26-27 revenue forecasts by 7%-8% and profit by 6%-7%.

Given the business thesis is unequivocally proven, Wilsons believes now is not the time to suggest the opportunity is all done now’ or the stock is too expensive’. The target is raised by $20 to $275. Overweight.

This report was published on November 29, 2024.

Target price is $275.00 Current Price is $251.89 Difference: $23.11
If PME meets the Wilsons target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $155.30, suggesting downside of -38.3%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 53.80 cents and EPS of 108.00 cents.
At the last closing share price the estimated dividend yield is 0.21%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 233.23.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 104.3, implying annual growth of 31.6%.
Current consensus DPS estimate is 52.0, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 241.5.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 68.60 cents and EPS of 138.80 cents.
At the last closing share price the estimated dividend yield is 0.27%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 181.48.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 143.2, implying annual growth of 37.3%.
Current consensus DPS estimate is 71.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 175.9.

Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PPE    PEOPLEIN LIMITED

Jobs & Skilled Labour Services – Overnight Price: $0.91

Wilsons rates ((PPE)) as Market Weight (3) –

Wilsons notes PeopleIn’s AGM highlighted no major deterioration in conditions and a reduction in net debt/earnings (EBITDA) to 1.7 times at September 2024 from 2.1 times at June 2024.

First-quarter FY25 earnings of $9.2m represent an -8% decline compared to the FY24 quarterly average, with management anticipating tough macroeconomic conditions to persist for the next six months.

Performance varied across segments, highlights the broker, with nursing under pressure, while Edmen, FTAI Infrastructure Inc (FIP) and Perigon Wealth Management showed resilience.

Wilsons lowers the FY25 earnings forecast by -7% and FY26-27 by -8%. The broker reduces the target price to $1.03 from $1.18 and retains an Overweight rating.

This report was published on November 29, 2024.

Target price is $1.03 Current Price is $0.91 Difference: $0.12
If PPE meets the Wilsons target it will return approximately 13% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY25:

Wilsons forecasts a full year FY25 dividend of 5.10 cents and EPS of 7.00 cents.
At the last closing share price the estimated dividend yield is 5.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.00.

Forecast for FY26:

Wilsons forecasts a full year FY26 dividend of 5.70 cents and EPS of 13.00 cents.
At the last closing share price the estimated dividend yield is 6.26%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.00.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

QBE    QBE INSURANCE GROUP LIMITED

Insurance – Overnight Price: $20.00

Jarden rates ((QBE)) as Buy (1) –

Jarden observes QBE Insurance has reiterated FY24 guidance for a combined operating ratio (COR) below 93.5%, supported by a multi-year de-risking strategy and portfolio rebalancing towards higher-margin international business.

Premium rate increases averaged 4.9% in the third quarter, down from 5.7% in the second quarter, while constant currency GWP growth year-to-date was 2%, impacted by non-core portfolio exits, explain the analysts.

Catastrophe (CAT) costs for the year to October reached -US$425m, equating to 74% of the budget, with Jarden anticipating a US$120m beat on FY24 CAT allowances.

The absence of out-of-cycle reserving updates reflects a robust balance sheet, highlights the broker, though adverse US harvest yields may result in FY24 Crop COR reaching 94%.

Jarden raises its target price to $21.80 from $20.90 and retains a Buy rating.

This report was published on November 28, 2024.

Target price is $21.80 Current Price is $20.00 Difference: $1.8
If QBE meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $20.70, suggesting upside of 3.5%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY24:

Jarden forecasts a full year FY24 dividend of 83.00 cents and EPS of 165.91 cents.
At the last closing share price the estimated dividend yield is 4.15%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.05.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 167.5, implying annual growth of N/A.
Current consensus DPS estimate is 70.1, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 11.9.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 90.00 cents and EPS of 172.10 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.62.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 179.2, implying annual growth of 7.0%.
Current consensus DPS estimate is 79.1, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 11.2.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

WEB    WEB TRAVEL GROUP LIMITED

Travel, Leisure & Tourism – Overnight Price: $5.15

Jarden rates ((WEB)) as Overweight (2) –

Jarden lowers its target price for Web Travel to $5.60 from $7.10, reflecting revised guidance and lower assumptions for revenue margins and terminal year earnings (EBITDA).

The broker notes the group continues to win market share, with the $10bn FY30 total transaction value (TTV) target unchanged.

The 1H FY25 performance highlights challenges, according to the analysts, with lower revenue margins stemming from a shift in customer and regional mix alongside higher costs.

Jarden observes ongoing issues in stabilising revenue margins, with management’s medium-term target reduced to 6.5% from over 7%. It’s felt cost control and operational leverage remain essential for a potential re-rating.

Management has reiterated a $150m buyback by the end of 2026. Jarden retains an Overweight rating, citing the group’s market share growth and positive outlook.

This report was published on November 28, 2024.

Target price is $5.60 Current Price is $5.15 Difference: $0.45
If WEB meets the Jarden target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $5.52, suggesting upside of 7.3%(ex-dividends)
The company’s fiscal year ends in March.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 16.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 31.21.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 19.9, implying annual growth of 5.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 25.9.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 9.00 cents and EPS of 25.30 cents.
At the last closing share price the estimated dividend yield is 1.75%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.36.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 27.0, implying annual growth of 35.7%.
Current consensus DPS estimate is 3.3, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 19.1.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

WJL    WEBJET GROUP LIMITED

Travel, Leisure & Tourism – Overnight Price: $0.85

Jarden rates ((WJL)) as Overweight (2) –

Jarden sees potential upside for Webjet Group, citing management’s commentary on a strong start to the second half.

The broker forecasts an 18% compound annual growth rate in earnings (EPS) from FY25 to FY28, reflecting confidence in the company’s growth trajectory.

First-half earnings (EBITDA) increased by only 1% year-on-year, which Jarden attributes to a weaker macroeconomic environment and the impact of the recent demerger.

Despite this result, the broker considers management’s guidance for broadly flat underlying FY25 earnings to be conservative if current positive trends persist.

Jarden maintains an Overweight rating for Webjet Group with a target price of $1.10.

This report was published on November 27, 2024.

Target price is $1.10 Current Price is $0.85 Difference: $0.25
If WJL meets the Jarden target it will return approximately 29% (excluding dividends, fees and charges).
The company’s fiscal year ends in March.

Forecast for FY25:

Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.18.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 2.00 cents and EPS of 6.40 cents.
At the last closing share price the estimated dividend yield is 2.35%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.28.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

---

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.

Click to view our Glossary of Financial Terms